§ 13F · FUND PROFILE
Versant Venture Management, LLC.
AUM · $163M (13F)Positions · 8Turnover · n/a · Q2Filed · Aug 12, 2026
CONCENTRATION
n/a
Top 10 holdings
NEW BUYS
0
No new positions
EXITS
0
No exits
SECTOR SHIFT
n/a
No prior quarter data
§ 01 · TOP HOLDINGS
The book · Q2 2026
FILED AUG 12, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q2 |
|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics, Inc. | 3.18M | $77M | 47.3% | ±0% |
| 2 | IPSC | Century Therapeutics, Inc. | 12.17M | $30M | 18.3% | ±0% |
| 3 | JBIO | Jade Biosciences, Inc. | 992K | $22M | 13.6% | −35% |
| 4 | LENZ | Lenz Therapeutics, Inc. | 2.66M | $15M | 9.3% | ±0% |
| 5 | CTNM | Contineum Therapeutics, Inc. | 543K | $9M | 5.5% | ±0% |
| 6 | CRSP | CRISPR Therapeutics AG | 149K | $8M | 5.0% | ±0% |
| 7 | SKYE | Skye Bioscience, Inc. | 2.01M | $1M | 0.9% | ±0% |
| 8 | OVASUSD | Tempest Therapeutics, Inc. | 270K | $299K | 0.2% | ±0% |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE VERSANT SIGNAL
AC read
Versant Venture Management, LLC is a Other fund managing $163 million in assets. The fund runs a focused portfolio of just 8 positions.
Read the full dossier →